Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

The interim results of a study of cerdulatinib in non-Hodgkin lymphoma showed partial responses (PRs) in most of the cohorts. The CLL/small lymphocytic leukemia population saw the highest rate activity with 67% of patients achieving a PR.

Additionally, a complete response was seen in the first patient with relapsed/refractory peripheral T-cell lymphoma to be enrolled on the study.